The study took a two-pronged approach. The investigators first examined an institutional cohort of 30 patients with BO-MBC, defined as synchronous or metachronous brain metastases in the complete absence of extracranial metastatic disease, treated between January 2017 and July 2024. They then turned to the National Cancer Database, a hospital-based registry jointly sponsored by the American College of Surgeons and the American Cancer Society that captures roughly 70 percent of newly diagnosed malignancies in the United States. From more than 1,500 accredited facilities, they identified 8,909 patients with metastatic breast cancer and synchronous brain metastases diagnosed between 2010 and 2020. Of these, 1,540 patients, or 17.3 percent, had brain-only disease, while the remaining 82.7 percent had brain metastases accompanied by concurrent extracranial metastases.

The clinicopathologic fingerprints of the two groups differed in striking ways. Patients with brain-only disease were more likely to have node-negative primary tumors, with 28.5 percent clinically node-negative at diagnosis compared with 20.1 percent of those with concurrent extracranial disease. They were also more likely to carry triple-negative tumors, at 26.0 percent versus 17.7 percent, and less likely to have hormone receptor-positive, HER2-negative disease, at 22.2 percent versus 31.3 percent. These differences were highly statistically significant and directionally consistent with earlier, smaller series suggesting that brain-only metastasis is enriched for aggressive, CNS-tropic tumor biology, particularly triple-negative and HER2-positive subtypes.

Treatment patterns diverged as well, and in a way that reveals how clinical decision-making is shaped by disease distribution. Patients with brain-only metastases were more likely to receive brain radiotherapy, at 54.8 percent versus 41.0 percent, yet paradoxically less likely to receive systemic therapy, at 67.2 percent versus 74.5 percent. The authors interpret this as a lingering reflex: when no overt disease exists outside the skull, clinicians have historically leaned on locoregional, CNS-directed treatment. Yet the survival analyses suggest this instinct may be due for revision, because systemic therapy was associated with the largest survival benefit precisely in the brain-only group.

Using overlap propensity score weighting, a statistical technique that reweights observational cohorts to mimic the covariate balance of a randomized trial, the team adjusted for age, race, ethnicity, comorbidity burden, molecular subtype, and treatment receipt. In unadjusted Kaplan-Meier analyses, median overall survival was 12.5 months for brain-only patients versus 10.6 months for those with concurrent extracranial disease. After adjustment, the brain-only group retained a lower hazard of death whether or not they received brain radiotherapy, with adjusted hazard ratios of 0.67 and 0.69 respectively, while radiotherapy conferred no statistically significant survival difference among patients with concurrent extracranial metastases. Most strikingly, brain-only patients who received systemic therapy had the most favorable outcomes of any subgroup, with an adjusted hazard ratio of 0.22 compared with extracranial-disease patients who received no systemic therapy.

The institutional cohort added granularity that national registries cannot provide, and it told a sobering story about where this disease actually fails. At a median follow-up of 26.5 months, median overall survival had not been reached, with one- and two-year survival rates of 97 and 90 percent. Median extracranial progression-free survival was 30.4 months, reflecting durable control of disease outside the brain. But median intracranial progression-free survival was only 14.6 months, and intracranial progression, whether parenchymal growth or the development of leptomeningeal disease, occurred in two-thirds of patients. Six patients, one-fifth of the cohort, eventually developed leptomeningeal disease, the diffuse seeding of the membranes surrounding the brain that remains one of the most feared complications in neuro-oncology.

That asymmetry, a body held in check while the brain progresses, is the biological heart of the paper. The central nervous system is a sanctuary site where the blood-brain barrier limits drug penetration, and the study documents how receptor biology can shift inside that sanctuary. Among 25 institutional patients who underwent neurosurgical resection, receptor discordance between the primary breast tumor and the brain metastasis was observed in 28 percent of cases, and every discordant event involved hormone receptor status, with no HER2 discordance. Three patients converted from hormone receptor-positive to hormone receptor-negative disease in the brain, and two converted in the opposite direction. Such conversions can silently invalidate a systemic regimen that was chosen based on the original tumor’s profile.

The radiation therapy findings demand careful reading. Within the brain-only group, patients treated with stereotactic radiosurgery or stereotactic radiotherapy showed better overall survival than those treated with whole brain radiation, with an adjusted hazard ratio of 0.76, and a similar association appeared in the extracranial-disease group. But the authors are emphatic that this should not be read as proof of modality superiority. Randomized trials comparing the two approaches have never shown a consistent survival advantage for stereotactic techniques; their established benefit lies in preserving neurocognitive function. Patients selected for radiosurgery in routine practice tend to have lower intracranial burden, better performance status, and more favorable prognoses, and the National Cancer Database does not capture tumor number, volume, location, symptoms, or salvage treatments, all of which drive modality selection. The survival signal almost certainly reflects selection bias rather than a direct treatment effect.

What the radiation data do support is a strategic argument. Because brain-only patients often live long enough for intracranial control and the late effects of CNS-directed therapy to dominate their quality of life, minimizing neurotoxicity becomes paramount. Neurocognitive-sparing stereotactic strategies, integrated with rigorous CNS surveillance and contemporary systemic therapy, may represent the optimal multidisciplinary framework for appropriately selected patients, even when the survival statistics alone cannot settle the question.

The study’s context is also a story about a therapeutic landscape in motion. Most patients in the national cohort were diagnosed before the widespread adoption of CNS-penetrant systemic agents, meaning the observed survival benefit of systemic therapy likely understates what is achievable today. In HER2-positive disease, the HER2CLIMB trial showed that adding tucatinib to trastuzumab and capecitabine produced a 47.3 percent intracranial response rate in patients with active brain metastases, while the antibody-drug conjugate trastuzumab deruxtecan achieved intracranial response rates of 73.3 percent in the phase II TUXEDO-1 trial and 62.3 percent overall in the phase 3b/4 DESTINY-Breast12 study, rising to 82.6 percent in previously untreated brain metastases. The CDK4/6 inhibitor abemaciclib has demonstrated blood-brain barrier penetration in hormone receptor-positive disease, and sacituzumab govitecan has shown emerging CNS activity in triple-negative breast cancer. As these agents increasingly control disease on both sides of the blood-brain barrier, the distinctions the study documents, between brain-only and widespread metastatic disease, between intracranial and extracranial failure, and between treatment effects that depend on disease distribution, will only grow more clinically consequential. The authors caution that registry limitations, including missing subtype data in roughly a quarter to a third of patients and the exclusion of metachronous brain metastases, mean these findings raise but do not establish the case for BO-MBC as a formal phenotype. What they establish beyond doubt is that the question now deserves prospective investigation in its own right.

Subject of Research: Brain-only metastatic breast cancer as a distinct clinical phenotype and its implications for radiation therapy and systemic treatment

Article Title: Brain-only metastatic breast cancer as a distinct clinical entity: evidence from national and institutional cohorts with implications for radiation therapy

Article References: Harrell, M., Kutuk, T., Gokun, Y., Upadhyay, R., Jhawar, S. R., Stover, D., Williams, N., Gatti-Mayes, M. E., Sizemore, G., LeFebvre, H., Grecula, J. C., Raval, R. R., Singh, R., Zhu, S., Blakaj, D. M., Chakravarti, A., Palmer, J. D., & Beyer, S. J. (2026). Brain-only metastatic breast cancer as a distinct clinical entity: evidence from national and institutional cohorts with implications for radiation therapy. Breast Cancer Research and Treatment, 219(3), Article 29. https://doi.org/10.1007/s10549-026-08092-3

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08092-3

Keywords: breast cancer, brain metastases, brain-only metastatic breast cancer, stereotactic radiosurgery, whole brain radiotherapy, National Cancer Database, triple-negative breast cancer, leptomeningeal disease, systemic therapy, radiation oncology, intracranial progression, CNS-penetrant therapies

Triple-negative breast cancer is defined by the absence of the three molecular handles that anchor most modern breast cancer therapy: the estrogen receptor, the progesterone receptor, and HER2. Without those targets, endocrine agents and HER2-directed drugs are ineffective, leaving cytotoxic chemotherapy as the systemic backbone of treatment. Although triple-negative tumors account for only about 10 to 15 percent of breast cancers, they carry a disproportionate share of the disease’s mortality because they tend to grow quickly, are more likely to metastasize, and historically have fewer therapeutic options. For patients whose tumors are caught early, the central treatment question is not whether chemotherapy helps but when it should be given.

That question is most acute for T1c tumors, which measure between one and two centimeters and have not spread to regional lymph nodes or distant sites. The T1cN0M0 designation describes a small, node-negative cancer, yet even at this stage triple-negative biology demands systemic therapy to reduce recurrence risk. The debate concerns sequencing. Neoadjuvant chemotherapy, delivered before surgery, offers the chance to shrink the tumor, potentially enabling less extensive operations, and provides real-time information about how the cancer responds to treatment. Adjuvant chemotherapy, given after surgery, achieves the same cytotoxic goal but leaves the surgeon operating on a tumor that has never been exposed to drugs. National guidelines leave room for either approach in this small-tumor setting, and practice varies considerably across institutions.

The reason sequencing remains contested is that neither strategy has demonstrated superior overall survival. Multiple prior analyses, including studies of the same National Cancer Database, have found that patients with clinically node-negative T1 triple-negative tumors fare equally well whether chemotherapy comes first or last. If survival outcomes are equivalent, the choice between the two approaches hinges on secondary benefits: the possibility of breast-conserving surgery, the prognostic information embedded in treatment response, and patient preference. The Johns Hopkins team, led by breast surgical oncology researcher Andrew Venardi, set out to sharpen that calculus by asking a more granular question: within this seemingly uniform early-stage population, which patients are actually likely to benefit from going first with chemotherapy?

The answer, they hypothesized, might lie in Ki-67, a nuclear protein expressed by cells that are actively dividing. Pathologists measure Ki-67 by immunohistochemistry, staining tumor samples and counting the percentage of positive cells, which yields a proliferation index reflecting how fast the cancer is growing. The logic connecting Ki-67 to neoadjuvant strategy is mechanistically straightforward: chemotherapy agents such as anthracyclines and taxanes preferentially kill rapidly proliferating cells, so tumors with a high fraction of dividing cells should, in principle, be more sensitive to upfront drug treatment. Previous studies have associated high Ki-67 expression with better responses to neoadjuvant chemotherapy in triple-negative disease, but the specific threshold that separates responders from non-responders in the earliest tumor category had not been clearly defined using large-scale national data.

To conduct the analysis, the researchers queried the National Cancer Database for female patients aged 18 and older diagnosed with T1N0M0 triple-negative breast cancer between 2018 and 2022 who underwent both chemotherapy and surgery. The National Cancer Database, jointly maintained by the American College of Surgeons and the American Cancer Society, captures roughly 70 percent of newly diagnosed cancer cases in the United States, providing the statistical power that single-institution series cannot match. Patients were divided into a neoadjuvant chemotherapy cohort and an adjuvant chemotherapy cohort. Because the two groups differ systematically in tumor size, grade, and other characteristics—surgeons and oncologists tend to select patients for upfront chemotherapy based on perceived risk—the team applied inverse probability of treatment weighting, a statistical technique that re-weights the cohorts to mimic the balance of a randomized trial.

The survival analysis produced a finding consistent with the existing literature: overall survival did not differ significantly between the neoadjuvant and adjuvant groups. Multivariate Cox regression, which adjusts for competing variables simultaneously, instead identified three factors associated with worse survival. Lymphovascular invasion, the presence of tumor cells within small blood or lymphatic vessels, signaled a higher risk of microscopic spread. The invasive lobular subtype, which arises in the milk-producing lobules rather than the ducts, and mixed lobular-ductal tumors were also linked to poorer outcomes. Lobular triple-negative cancers are rare and biologically distinct, and recent registry-based studies have shown they can carry worse survival despite appearing indolent, so their emergence as an adverse marker in this dataset aligns with a growing body of evidence.

The most consequential result came from the response analysis. Among patients who received neoadjuvant chemotherapy, those who achieved a pathologic complete response—meaning no residual invasive cancer was found in the breast or lymph nodes at the time of surgery—had markedly better survival than those who did not. Non-responders faced a hazard ratio of 3.59 for worse overall survival compared with patients who achieved a complete response. This echoes the findings of a large meta-analysis showing that pathologic complete response in triple-negative breast cancer is strongly associated with improved long-term event-free and overall survival. In other words, while the timing of chemotherapy may not change survival on average, achieving eradication of the tumor before surgery identifies a subgroup whose prognosis is transformed.

That is where the Ki-67 threshold enters. Using a receiver operating characteristic curve, the researchers plotted the relationship between Ki-67 expression and pathologic complete response and applied the maximum Youden index, a standard method for finding the cutoff point that best balances sensitivity and specificity. The threshold that emerged was 45.8 percent. Patients whose tumors expressed Ki-67 at or above that level achieved a pathologic complete response rate of 45.3 percent, while those below it responded at a rate of only 21.8 percent. Expressed differently, a high proliferation index more than doubled the odds that upfront chemotherapy would completely eliminate the tumor. Logistic regression confirmed Ki-67 expression as an independent predictor of complete response, suggesting the association held after accounting for other tumor characteristics.

The clinical implications are tangible for a patient population that often faces an anxious choice. A woman with a 1.5-centimeter, node-negative triple-negative tumor whose biopsy shows a Ki-67 index of 50 percent now has registry-scale evidence that chemotherapy before surgery is likely to produce a complete response, with the dual benefits of maximal prognostic information and a survival outcome that appears markedly better than that of non-responders. Conversely, a patient with a low proliferation index may reasonably opt for surgery first, since her probability of achieving a complete response is lower and adjuvant chemotherapy delivers equivalent survival. The authors emphasize that the study is retrospective and that Ki-67 measurement itself has well-known variability between laboratories and staining protocols, so the 45.8 percent cutoff should be validated prospectively before it reshapes guidelines. Still, as the field moves from one-size-fits-all recommendations toward personalized sequencing in stage I triple-negative breast cancer, a routine pathology marker already on every diagnostic report may prove to be the deciding variable.

Subject of Research: Ki-67 expression as a predictor of pathologic complete response to neoadjuvant chemotherapy in early-stage triple-negative breast cancer

Article Title: Ki-67 expression and rates of pathologic complete response in T1cN0M0 triple-negative breast cancer: a national cancer database analysis

Article References: Venardi, A., Shojaeian, F., Diaz, S., Schuster, C. R., Rath, P., Shaid, I., Singh, A., Santa-Maria, C., & Sogunro, O. (2026). Ki-67 expression and rates of pathologic complete response in T1cN0M0 triple-negative breast cancer: a national cancer database analysis. Breast Cancer Research and Treatment, 219(3), Article 21. https://doi.org/10.1007/s10549-026-08086-1

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08086-1

Keywords: triple-negative breast cancer, Ki-67, neoadjuvant chemotherapy, pathologic complete response, National Cancer Database, T1cN0M0, proliferation index, biomarker, breast surgical oncology, lymphovascular invasion, invasive lobular carcinoma, personalized treatment